Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005580 · ClinicalTrials.gov registry record · Phase 1
Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00005580 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 54 participants.
The verdict
NCT00005580, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of bryostatin 1 plus fludarabine in treating patients who have chronic lymphocytic leukemia or relapsed, indolent non-Hodgkin's lymphoma.
Interventions
- DRUG fludarabine phosphate
- DRUG bryostatin 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 1998-09 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005580
The ClinicalTrials.gov registry entry for NCT00005580 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fludarabine phosphate is the first listed.
NCT00005580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005580 about?
NCT00005580 is a clinical study titled "Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of bryostatin 1 plus fludarabine in treating patients who have chronic ...
What is the current status of trial NCT00005580?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 1998-09. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00005580?
The interventions under investigation include: fludarabine phosphate (DRUG), bryostatin 1 (DRUG).
Who is sponsoring clinical trial NCT00005580?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.